Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48  Weeks: 307 Open-Label Extension Study

ConclusionPegcetacoplan sustained long-term improvements in hemoglobin concentrations, fatigue reduction, and transfusion burden. Long-term safety findings corroborate the favorable profile established for pegcetacoplan.Trial identifier, NCT03531255.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research